|
Ixico PLC on Tuesday said its loss narrowed in the first half of its financial year, as revenue growth supported its expectations for continued momentum in the second half. The London-based medical analytics company said its pretax loss narrowed to £889,000 in the six months that ended March 31 from £1.5 million a year before. Revenue grew 20% to £3.2 million from £2.5 million, ‘putting the company in a strong position to deliver or exceed guidance’, Ixico said. Cost of sales rose by just 6.7% to £1.6 million from £1.5 million, and total operating expenses were reduced 3.4% during the six-month period to £2.8 million from £2.9 million. Loss before interest, tax, depreciation and amortisation was £700,000, narrowed from £1.3 million a year prior. The order book stood at £13.1 million on March 31, up 3.1% from £12.7 million a year before, Ixico said. ‘The first half of 2025 indicates that our ’innovate lead scale’ strategy has created the foundations for a return to growth driven by the diversification of revenue streams, therapeutic areas and market verticals, together with the scope extension of existing client programs,’ said Chief Executive Officer Bram Goorden. ‘It has been a positive first six months defined by disciplined commercial execution, scientific innovation and truly differentiated technology development. My conviction has been further strengthened that the company is going to make an accelerated impact in the thriving space of neurodegenerative disease research.’ Shares in Ixico were up 7.5% at 9.68 pence each in London on Tuesday morning. The stock has risen 36% over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
